In furtherance to the letter dated 24th September, 2019, with respect to, order passed by Securities and Exchange Board of India (SEBI) in the matter of issuance of Global Depository Receipts (GDR) by the Company, Morepen Laboratories has informed that the Company has clarified that the said matter was pertaining to the year 2003 which has been finally settled by the SEBI today. Further, there is no impact on the existing securities listed with the Stock Exchanges as well as no financial implications on the business operation of the Company, of the said order. Additionally, with reference to the ongoing preferential issue of fully convertible warrants (to be converted within 18 months), the company is seeking guidance regarding implication of the SEBIs order and process to be followed to complete the said preferential issue of warrants.
The above information is a part of company’s filings submitted to BSE.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1532.85 |
Dr. Reddys Lab | 5812.50 |
Cipla | 1403.90 |
Zydus Lifesciences | 1104.45 |
Lupin | 1661.90 |
View more.. |